Alto Neuroscience has raised $120m that will fund pivotal trials of its recently acquired candidate for treatment-resistant depression.
FDA seeks input on Makary’s voucher pilot
The FDA is seeking feedback ahead of a public meeting this summer to evaluate the progress of a voucher pilot that has so far accelerated


